Tybriva 140mg Ibrutinib Capsule Description:
Tybriva 140mg is a targeted therapy. It inhibits the function of Bruton’s tyrosine kinase (BTK). BTK is a key signaling molecule of the B-cell receptor signaling complex that plays an important role in the survival of malignant B cells. It blocks signals that stimulate malignant B cells to grow and divide uncontrollably. It is not a chemotherapy drug but one of what are termed “targeted therapies.”
Ibrutinib is used to treat certain types of non-Hodgkin lymphoma, including mantle cell lymphoma (MCL), Waldenstrom’s macroglobulinemia, and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in people with or without 17p deletion. However, it has not been shown that it can improve symptoms or lengthen survival time in people with this type of lymphoma.
Pale skin, easy bruising or bleeding; fever, chills, flu symptoms;nausea, diarrhea; tired feeling; rash; or muscle pain, bone pain.
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it.